Abstract
Objectives: A significant proportion of high grade endometrial cancer (HGENCA) over-express HER2 (ERBB2) yet clinical trials have failed to demonstrate any anti-tumor activity utilizing trastuzumab. A truncated p95HER2 variant has been suggested to confer trastuzumab resistance in HER2 over-expressing breast cancer. We sought to characterize the relationship between total HER2 protein expression, HER2 gene amplification, and expression of the p95HER2 truncated variant in HGENCA.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
